[go: up one dir, main page]

NO951166L - 3-,8-substituerte deuteroporfyrinderivater, farmasöytiske preparater som inneholder dem, og fremgangsmåter for fremstilling av dem - Google Patents

3-,8-substituerte deuteroporfyrinderivater, farmasöytiske preparater som inneholder dem, og fremgangsmåter for fremstilling av dem

Info

Publication number
NO951166L
NO951166L NO951166A NO951166A NO951166L NO 951166 L NO951166 L NO 951166L NO 951166 A NO951166 A NO 951166A NO 951166 A NO951166 A NO 951166A NO 951166 L NO951166 L NO 951166L
Authority
NO
Norway
Prior art keywords
pct
processes
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
NO951166A
Other languages
English (en)
Other versions
NO303732B1 (no
NO951166D0 (no
Inventor
Christoph-Stephan Hilger
Franz-Karl Maier
Heinz Gries
Ulrich Niedballa
Johannes Platzek
Mary Lee-Vaupel
Wolfgang Ebert
Jurgen Conrad
Josef Gaida
Original Assignee
Diagnostikforschung Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostikforschung Inst filed Critical Diagnostikforschung Inst
Publication of NO951166L publication Critical patent/NO951166L/no
Publication of NO951166D0 publication Critical patent/NO951166D0/no
Publication of NO303732B1 publication Critical patent/NO303732B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19951166A 1992-09-28 1995-03-27 Porfyrinkompleksforbindelser, farmasoytisk middel inneholdende minst ett av disse og anvendelse av minst ett av disse for fremstilling av midler for NMR- eller radiodiagnostikk, samt for radioterapi NO303732B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4232925A DE4232925A1 (de) 1992-09-28 1992-09-28 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
PCT/EP1993/002645 WO1994007894A1 (de) 1992-09-28 1993-09-28 3-,8-substituierte deuteroporphyrinderivate, diese enthaltende pharmazeutische mittel und verfahren zu ihrer herstellung

Publications (3)

Publication Number Publication Date
NO951166L true NO951166L (no) 1995-03-27
NO951166D0 NO951166D0 (no) 1995-03-27
NO303732B1 NO303732B1 (no) 1998-08-24

Family

ID=6469326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19951166A NO303732B1 (no) 1992-09-28 1995-03-27 Porfyrinkompleksforbindelser, farmasoytisk middel inneholdende minst ett av disse og anvendelse av minst ett av disse for fremstilling av midler for NMR- eller radiodiagnostikk, samt for radioterapi

Country Status (11)

Country Link
US (1) US5849259A (no)
EP (1) EP0662972B1 (no)
JP (1) JPH08504399A (no)
AT (1) ATE226953T1 (no)
CA (1) CA2145509C (no)
DE (2) DE4232925A1 (no)
DK (1) DK0662972T3 (no)
ES (1) ES2186677T3 (no)
NO (1) NO303732B1 (no)
WO (1) WO1994007894A1 (no)
ZA (1) ZA937194B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031219A1 (en) * 1994-05-11 1995-11-23 Schering Aktiengesellschaft The use of porphyrin-complex or expanded porphyrin-complex compounds as localization diagnosticum for infarction or necrosis
DE19719033C1 (de) * 1997-04-29 1999-01-28 Schering Ag Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel
EP0885616A1 (de) * 1997-06-20 1998-12-23 Schering Aktiengesellschaft Verwendung von intravenösen Kontrastmitteln sowie Vorrichtungen für die Projektionsmammographie
DE19845782C1 (de) * 1998-09-22 2000-04-13 Schering Ag Verfahren zur Herstellung von Metallporphyrin-Metallkomplex-Konjugaten
US6194566B1 (en) 1997-12-02 2001-02-27 Schering Aktiengesellschaft Process for the production of metalloporphyrin-metal complex conjugates
DE19825512A1 (de) * 1998-06-02 1999-12-09 Schering Ag 3-,8-subsituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel, Verfahren zu ihrer Herstellung und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6136841A (en) * 1998-06-02 2000-10-24 Schering Aktiengesellschaft 3-, 8-substituted deuteroporphyrin derivatives, pharmaceutical agents that contain the latter, process for their production and their use in photodynamic therapy and MRI diagnosis
DE19835082A1 (de) * 1998-07-24 2000-02-03 Schering Ag Paramagnetische 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel, Verfahren zu ihrer Herstellung und ihre Verwendung für das Nekrose- und Infarkt-MR-Imaging
US6251367B1 (en) 1998-07-24 2001-06-26 Schering Aktiengesellschaft Paramagnetic 3-,8-substituted deuteroporphyrin derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
IL146126A0 (en) * 1999-04-30 2002-07-25 Slil Biomedical Corp Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
ES2269138T3 (es) * 1999-04-30 2007-04-01 Cellgate, Inc. Poliaminas y su uso en terapia.
WO2001040233A1 (en) * 1999-11-30 2001-06-07 Photochemical Co., Ltd. Nitroimidazole-supporting porphyrin complex
DE19961533A1 (de) * 1999-12-20 2002-03-28 Steag Micro Tech Gmbh Vorrichtung und Verfahren zum Behandeln von Substraten
US7097826B2 (en) * 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US20030072715A1 (en) * 2000-08-02 2003-04-17 Benjamin Frydman Cyclic polyamine compounds for cancer therapy
AU2002235126A1 (en) 2000-11-08 2002-05-21 Slil Biomedical Corporation Novel polyamine analog-amino acid conjugates useful as anticancer agents
WO2002096366A2 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
WO2002096417A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
JP5000050B2 (ja) * 2001-08-31 2012-08-15 浩 前田 抗腫瘍剤及びその製造方法
DE10240343A1 (de) * 2002-08-27 2004-03-11 Schering Ag Peroxynitrit-Umlagerungskatalysatoren
GB2397067B (en) 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
JP5823988B2 (ja) * 2011-01-31 2015-11-25 国立大学法人宇都宮大学 ポルフィリン型骨格を有する化合物の金属錯体の製造方法
CN102363619A (zh) * 2011-11-18 2012-02-29 中国医学科学院生物医学工程研究所 水溶性原卟啉化合物及制备方法及用途
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2018096082A1 (en) 2016-11-28 2018-05-31 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
AU2019382881B2 (en) 2018-11-23 2025-06-12 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485086A (en) * 1983-04-11 1984-11-27 Wong Dennis W Radiolabeled tumor imaging agent and method of preparation
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
DE3827940A1 (de) * 1988-08-13 1990-03-01 Schering Ag 13,17-propionsaeure- und propionsaeurederivat- substituierte porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor

Also Published As

Publication number Publication date
WO1994007894A1 (de) 1994-04-14
US5849259A (en) 1998-12-15
JPH08504399A (ja) 1996-05-14
NO303732B1 (no) 1998-08-24
EP0662972A1 (de) 1995-07-19
CA2145509C (en) 2005-04-05
ATE226953T1 (de) 2002-11-15
DK0662972T3 (da) 2003-03-03
ES2186677T3 (es) 2003-05-16
ZA937194B (en) 1994-04-21
DE4232925A1 (de) 1994-03-31
CA2145509A1 (en) 1994-04-14
NO951166D0 (no) 1995-03-27
DE59310310D1 (de) 2002-12-05
EP0662972B1 (de) 2002-10-30

Similar Documents

Publication Publication Date Title
NO951166L (no) 3-,8-substituerte deuteroporfyrinderivater, farmasöytiske preparater som inneholder dem, og fremgangsmåter for fremstilling av dem
ATE224888T1 (de) Pyridylalken- und pyridylalkin-säureamide als cytostatika und immunosuppressive arzneimittel
AU2002305143A1 (en) Pyrazolo'1,5-a!pyridine derivatives
IL108520A (en) 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MY132642A (en) Naphthyridine derivatives
DE60112609D1 (en) Pyrazolopyridine
ATE223912T1 (de) Pyridylalkan-säureamide als cytostatika und immunosupressive arzneimittel
NO20035583D0 (no) Imidazo` 1,2-A pyridinderivater for profylakse og behandling av herpes virale infeksjoner
AR007828A1 (es) Compuestos derivados de piridilpirrol, procedimiento de preparacion y composiciones farmaceuticas conteniendo los mismos
DE60220525D1 (de) Pyrazolo-pyridine für die behandlung von herpes-ansteckungen
AU2002239348A1 (en) Pyrazolopyridine derivatives
SE8405754L (sv) 7-karboximetoxi-furo-(3,4-c)-pyridinderivat, framstellning derav och terapeutiska kompositioner innehallande dem
HU9601217D0 (en) Antracyclinone derivatives and their use for treating amyloidosis
ES8200094A1 (es) Procedimiento para la obtencion de alquilureas
DK0701440T3 (da) Tri(platin)komplekser
FR2700165B1 (fr) Dérivés de pyrrolidine, leur préparation et les médicaments les contenant.
BG105089A (en) 2-aminopyridines containing fused ring substituents as nitric oxide synthesis inhibitors
ATE145647T1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

MK1K Patent expired